Epithelial Ovarian Cancer

Oncology·MeSH: Carcinoma, Ovarian Epithelial

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

10 drugs in development·8 companies·19 clinical trials

Drug Pipeline by Phase

Phase 3(2)

Drug	Company
niraparib	Imunon, Inc. (IMNN)
rina-s	GENMAB A/S (GNMSF)

Phase 2(3)

Drug	Company
Mirvetuximab Soravtansine	AbbVie Inc. (ABBV)
pegfilgrastim	Bolt Biotherapeutics, Inc. (BOLT)
torl-1-23	Bolt Biotherapeutics, Inc. (BOLT)

Phase 1(2)

Drug	Company
itil-306	Instil Bio, Inc. (TIL)
lira-cel	Anixa Biosciences Inc (ANIX)

Phase 1/Phase 2(3)

Drug	Company
imnn-001	Imunon, Inc. (IMNN)
rina-s	Genmab A/S (GMAB)
skb264	CHINA PHARMA HOLDINGS, INC. (CPHI)

BioSniper tracks 10 drugs in development for Epithelial Ovarian Cancer across 8 companies.

There are 19 clinical trials targeting Epithelial Ovarian Cancer tracked by BioSniper.

The estimated prevalence of Epithelial Ovarian Cancer is approximately 24.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.